Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation

In type 1 diabetes (T1D) the immune system attacks insulin‐producing pancreatic β‐cells. Unfortunately, our ability to curb this pathogenic autoimmune response in a disease‐ and organ‐specific manner is still very limited due to the inchoate understanding of the exact nature and the kinetics of the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism Jg. 15; H. 7; S. 581 - 592
Hauptverfasser:	Schneider, D. A., Kretowicz, A. M., von Herrath, M. G.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Oxford, UK Blackwell Publishing Ltd 01.07.2013 Wiley Subscription Services, Inc
Schlagworte:	Animals Autoimmune diseases Autoimmunity beta cell Biomedical Research - trends clinical trial Diabetes diabetes mellitus Diabetes Mellitus, Type 1 - immunology Diabetes Mellitus, Type 1 - prevention & control Diabetes Mellitus, Type 1 - therapy Humans Immunotherapy - trends islets Islets of Langerhans Transplantation - immunology Islets of Langerhans Transplantation - trends Pancreas Pancreas - immunology Pancreas Transplantation - trends transplantation type 1 diabetes
ISSN:	1462-8902, 1463-1326, 1463-1326
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In type 1 diabetes (T1D) the immune system attacks insulin‐producing pancreatic β‐cells. Unfortunately, our ability to curb this pathogenic autoimmune response in a disease‐ and organ‐specific manner is still very limited due to the inchoate understanding of the exact nature and the kinetics of the immunological pathomechanisms that lead to T1D. None of the clinical immune interventions thus far, which focused primarily on new‐onset disease, were successful in producing lasting remission or curbing recurrent autoimmunity. However, these studies do provide us access to a tremendous amount of clinical data and specimens, which will aid us in revising our therapeutical approaches and defining the highly needed paradigm shift in T1D immunotherapy. Analysing the foundation and the results of the most current T1D immunotherapeutic trials, this article gives an outlook for future directions of the field.
Bibliographie:	ArticleID:DOM12046 ark:/67375/WNG-93ZDWDD8-7 istex:41A60505819F10D5271E4D949D3EF694B0908158 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
ISSN:	1462-8902 1463-1326 1463-1326
DOI:	10.1111/dom.12046